Author Index

Abdul-Wahid, S. *see* Georges, A.-J., 313
Anders, E.M., Scalzo, A.A. and White, D.O. Mitogenic activity of influenza virus and haemagglutinin, 241
Arden, N.H. *see* Kendal, A.P., 274
Armand, J. *see* Cadoz, M., 340
Arminjon, F. *see* Cadoz, M., 340
Ashworth, L.A.E. *see* Robinson, A., 11
Auerbach, D. *see* Strassburg, M.A., 109
Aynor, Y. *see* Kark, J.D., 117
Azuma, I. *see* Ishihara, C., 370
Azuma, I. *see* Nishimura, K., 379
Barry, R.D. *see* Tannock, G.A., 277
Bearman, J.E. *see* Gross, E.M., 283
Bengtsson, E. *see* Niklasson, B., 123
Beraud, A.M. *see* Georges, A.-J., 313
Bergman, M. *see* Bottiger, M., 113
Bhargava, M. *see* Wright, P.F., 305
Bodicky, C. *see* Regenstein, F.G., 27
Boltutsy, L.G. *see* Stanislavsky, E.S., 128
Boolk, V.F. *see* Stanislavsky, E.S., 128
Bos, E. *see* van Meel, F.C.M., 375
Boslego, J.W. *see* Tramont, E.C., 3
Bos, T.J. *see* Nayak, D.P., 165
Böttiger, M., Christenson, B., Taranger, J. and Bergman, M. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of school children, 113
Boudreault, A. and Thibodeau, L. Mouse response to influenza immunosomes, 231
Brand, C.M., Liew, F.Y. and Gething, M.-J. Host antigens associated with haemagglutinin, 252
Brown, L.E. *see* Katz, J.M., 257
Brown, L.E. *see* Yamada, A., 195
Bryce, D.A. *see* Tannock, G.A., 333
Buchan, A., Skinner, G.R.B., Fuller, A., Hartley, C., Hallworth, J., Stocker, D., Melling, J. and Wiblin, C. Control of herpes simplex virus infections of the genital tract by vaccination, 49
Cabrera-Contreras, R., Plescia, O., Solotorovsky, M. and Lynn, M. Enhancement of immunogenic activity of ribosomal preparations from *Haemophilus influenzae* by various adjuvants, 103
Cadoz, M., Armand, J., Arminjon, F., Gire, R. and Lafaix, Ch. Tetravalent (A,C,Y,W 135) meningococcal vaccine in children: immunogenicity and safety, 340
Campbell, C.H. Immunogenicity of bluetongue virus inactivated by gamma irradiation, 401
Cavanagh, D. Viral and bacterial vectors of immunogenes, 45
Christenson, B. *see* Böttiger, M., 113
Compans, R.W. *see* Pfeifer, J.B., 189
Cox, N.J. *see* Kendal, A.P., 263
Crouch, C.F. Vaccination against enteric rota and coronaviruses in cattle and pigs: enhancement of lactogenic immunity, 284
Davis, A.R. *see* Nayak, D.P., 165
DeBorde, D.C. *see* Maassab, H.F., 355
Desselberger, U. *see* Elliott, R.M., 182
Dionyssopoulou, E. *see* Matsaniotis, N., 297
Doel, T.R. Prospects for improved foot and mouth disease vaccines, 35
Dorner, F. and McDonel, J.L. Bacterial toxin vaccines, 94
Elliott, R.M., Yuanji, G. and Desselberger, U. Protein and nucleic acid analysis of influenza C viruses isolated from pigs and man, 182
Fatkhinurova, T.I. *see* Stanislavsky, E.S., 128
Ffrench, R.A. *see* Katz, J.M., 257
Friesen, H.-J. *see* Johannsen, R., 235
Fritzell, B. *see* Georges, A.-J., 313
Fuller, A. *see* Buchan, A., 49
García-Sáinz, J.A., Ruiz-Puente, J., Jiménez-Paredes, J., González-Pacheco, M. and Villava-Posada, H. Comparative biological activies of whole cell pertussis vaccine and a new acellular preparation, 23
Garten, W., Kuroda, K., Schuy, W., Naruse, H., Scholtissek, C. and Klenk, H.-D. Haemagglutinin transport mutants, 227
Georges, A.-J., Tible, F., Meunier, D.-M.-Y., Gonzalez, J.-P., Beraud, A.M., Sissoko-Dybdahl, N.-R., Abdul-Wahid, S., Fritzell, B., Girard, M. and Georges-Courbot, M.-C. Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine, 313
Georges-Courbot, M.-C., 313
Gething, M.-J. *see* Brand, C.M., 252
Geyer, R. *see* Herrler, G., 205
Girard, M. *see* Georges, A.-J., 313
Gire, R. *see* Cadoz, M., 340
Gladus, M.A. *see* Stanislavsky, E.S., 128
Gonczol, E. *see* Hudecz, F., 300
Gonzalez, J.-P. *see* Georges, A.-J., 313
González-Pacheco, M. *see* García-Sáinz, J.A., 23
Greenland, S. *see* Strassburg, M.A., 109
Grishina, I.A. *see* Krokhina, M.A., 316
Grishina, I.A. *see* Stanislavsky, E.S., 128
Gross, E.M. and Bearman, J.E. Post-exposure rabies prophylaxis; establishing effectiveness of abbreviated treatments, 283
Gruschkau, H. *see* Johannsen, R., 235
Habel, L.A. *see* Strassburg, M.A., 109
Hallworth, J. *see* Buchan, A., 49
Hamada, N. *see* Ishihara, C., 370
Hanson, R.P. *see* Shuaib, M.A., 385
Hartley, C. *see* Buchan, A., 49
Heiberg, D. *see* Zahradnik, J.M., 407
Herrler, G., Geyer, R., Stirm, S. and Klenk, H.-D. Inhibition with rat α_1-macroglobulin of haemagglutinin by influenza C virus, 205
Hinz, J. *see* Johannsen, R., 235
Hirabayashi, Y. *see* Suzuki, Y., 201
Hollinger, F.B. *see* Zahradnik, J.M., 407
Homma, M. *see* Hongo, S., 223
Homma, M. *see* Kitame, F., 211
Hongo, S., Sugawara, K., Homma, M. and Nakamura, K. Effects of glycosylation on the conformation and antigenicity of influenza C viral glycoproteins, 223
Hosaka, Y., Sasao, F. and Ohara, R. Cell-mediated lysis of heat-inactivated influenza virus-coated murine target, 245
Hudecz, F., Gonczol, E. and Plotkin, S.A. Preparation of highly purified human cytomegalovirus envelope antigen, 300
Iida, J. *see* Ishihara, C., 370
Irons, L.I. *see* Robinson, A., 11
Ishihara, C., Hamada, N., Yamamoto, K. Iida, J., Azuma, I. and Yamamura, Y. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice, 370
Jabbar, M.A. *see* Nayak, D.P., 165
Jackson, D.C. *see* Nestorowicz, A.N., 175
Jasman, R.L. *see* Woodard, L.F., 137
Jeggo, M.H. and Wardley, R.C. Bluetongue vaccine: cells and/or antibodies, 57
Jiménez-Paredes, J. *see* García-Sáinz, J.A., 23
Johannsen, R., Moser, H., Hinz, J., Friesen, H.-J. and Gruschkau, H. Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion, 235
Johnson, P.R. *see* Wright, P.F., 305
Joo, I. *see* Stanislavsky, E.S., 128
Kendal, A.P., Patriarca, P.A. and Arden, N.H. Policies and outcomes for control of influenza among the elderly in the USA, 274
Kark, J.D., Aynor, Y. and Peters, C.J. A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal *versus* subcutaneous injection, 117
Karzon, D.T. *see* Wright, P.F., 305
Kattamis, C. *see* Matsaniotis, N., 297
Katz, J.M., Brown, L.E., Ffrench, R.A. and White, D.O. Murine helper T lymphocyte response to influenza virus: recognition of haemagglutinin by subtype-specific and cross-reactive T cell clones, 257
Kendal, A.P. and Cox, N.J. Forecasting the epidemic potential of influenza virus variants based on their molecular properties, 263
Kida, H. *see* Shimizu, K., 207
Khaitov, R.M. *see* Petrov, R.V., 392
Kharitonenkov, I.G. *see* Petrov, R.V., 392
Kida, H., Yoden, S. Kuwabara, M. and Yanagawa, R. Interference with a conformational change in the haemagglutinin molecule of influenza virus by antibodies as a possible neutralization mechanism, 219

Author Index

Abdul-Wahid, S. *see* Georges, A.-J., 313
Anders, E.M., Scalzo, A.A. and White, D.O. Mitogenic activity of influenza virus and haemagglutinin, 241
Arden, N.H. *see* Kendal, A.P., 274
Armand, J. *see* Cadoz, M., 340
Arminjon, F. *see* Cadoz, M., 340
Ashworth, L.A.E. *see* Robinson, A., 11
Auerbach, D. *see* Strassburg, M.A., 109
Aynor, Y. *see* Kark, J.D., 117
Azuma, I. *see* Ishihara, C., 370
Azuma, I. *see* Nishimura, K., 379
Barry, R.D. *see* Tannock, G.A., 277
Bearman, J.E. *see* Gross, E.M., 283
Bengtsson, E. *see* Niklasson, B., 123
Beraud, A.M. *see* Georges, A.-J., 313
Bergman, M. *see* Bottiger, M., 113
Bhargava, M. *see* Wright, P.F., 305
Bodicky, C. *see* Regenstein, F.G., 27
Boltutsy, L.G. *see* Stanislavsky, E.S., 128
Boolk, V.F. *see* Stanislavsky, E.S., 128
Bos, E. *see* van Meel, F.C.M., 375
Boslego, J.W. *see* Tramont, E.C., 3
Bos, T.J. *see* Nayak, D.P., 165
Böttiger, M., Christenson, B., Taranger, J. and Bergman, M. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of school children, 113
Boudreault, A. and Thibodeau, L. Mouse response to influenza immunosomes, 231
Brand, C.M., Liew, F.Y. and Gething, M.-J. Host antigens associated with haemagglutinin, 252
Brown, L.E. *see* Katz, J.M., 257
Brown, L.E. *see* Yamada, A., 195
Bryce, D.A. *see* Tannock, G.A., 333
Buchan, A., Skinner, G.R.B., Fuller, A., Hartley, C., Hallworth, J., Stocker, D., Melling, J. and Wiblin, C. Control of herpes simplex virus infections of the genital tract by vaccination, 49
Cabrera-Contreras, R., Plescia, O., Solotorovsky, M. and Lynn, M. Enhancement of immunogenic activity of ribosomal preparations from *Haemophilus influenzae* by various adjuvants, 103
Cadoz, M., Armand, J., Arminjon, F., Gire, R. and Lafaix, Ch. Tetravalent (A,C,Y,W 135) meningococcal vaccine in children: immunogenicity and safety, 340
Campbell, C.H. Immunogenicity of bluetongue virus inactivated by gamma irradiation, 401
Cavanagh, D. Viral and bacterial vectors of immunogenes, 45
Christenson, B. *see* Böttiger, M., 113
Compans, R.W. *see* Pfeifer, J.B., 189
Cox, N.J. *see* Kendal, A.P., 263
Crouch, C.F. Vaccination against enteric rota and coronaviruses in cattle and pigs: enhancement of lactogenic immunity, 284
Davis, A.R. *see* Nayak, D.P., 165
DeBorde, D.C. *see* Maassab, H.F., 355
Desselberger, U. *see* Elliott, R.M., 182
Dionyssopoulou, E. *see* Matsaniotis, N., 297
Doel, T.R. Prospects for improved foot and mouth disease vaccines, 35
Dorner, F. and McDonel, J.L. Bacterial toxin vaccines, 94
Elliott, R.M., Yuanji, G. and Desselberger, U. Protein and nucleic acid analysis of influenza C viruses isolated from pigs and man, 182
Fatkhinurova, T.I. *see* Stanislavsky, E.S., 128
Ffrench, R.A. *see* Katz, J.M., 257
Friesen, H.-J. *see* Johannsen, R., 235
Fritzell, B. *see* Georges, A.-J., 313
Fuller, A. *see* Buchan, A., 49
García-Sáinz, J.A., Ruiz-Puente, J., Jiménez-Paredes, J., González-Pacheco, M. and Villava-Posada, H. Comparative biological activies of whole cell pertussis vaccine and a new acellular preparation, 23
Garten, W., Kuroda, K., Schuy, W., Naruse, H., Scholtissek, C. and Klenk, H.-D. Haemagglutinin transport mutants, 227
Georges, A.-J., Tible, F., Meunier, D.-M.-Y., Gonzalez, J.-P., Beraud, A.M., Sissoko-Dybdahl, N.-R., Abdul-Wahid, S., Fritzell, B., Girard, M. and Georges-Courbot, M.-C. Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine, 313
Georges-Courbot, M.-C., 313
Gething, M.-J. *see* Brand, C.M., 252
Geyer, R. *see* Herrler, G., 205
Girard, M. *see* Georges, A.-J., 313
Gire, R. *see* Cadoz, M., 340
Gladus, M.A. *see* Stanislavsky, E.S., 128
Gonczol, E. *see* Hudecz, F., 300
Gonzalez, J.-P. *see* Georges, A.-J., 313
González-Pacheco, M. *see* García-Sáinz, J.A., 23
Greenland, S. *see* Strassburg, M.A., 109
Grishina, I.A. *see* Krokhina, M.A., 316
Grishina, I.A. *see* Stanislavsky, E.S., 128
Gross, E.M. and Bearman, J.E. Post-exposure rabies prophylaxis; establishing effectiveness of abbreviated treatments, 283
Gruschkau, H. *see* Johannsen, R., 235
Habel, L.A. *see* Strassburg, M.A., 109
Hallworth, J. *see* Buchan, A., 49
Hamada, N. *see* Ishihara, C., 370
Hanson, R.P. *see* Shuaib, M.A., 385
Hartley, C. *see* Buchan, A., 49
Heiberg, D. *see* Zahradnik, J.M., 407
Herrler, G., Geyer, R., Stirm, S. and Klenk, H.-D. Inhibition with rat α_1-macroglobulin of haemagglutinin by influenza C virus, 205
Hinz, J. *see* Johannsen, R., 235
Hirabayashi, Y. *see* Suzuki, Y., 201
Hollinger, F.B. *see* Zahradnik, J.M., 407
Homma, M. *see* Hongo, S., 223
Homma, M. *see* Kitame, F., 211
Hongo, S., Sugawara, K., Homma, M. and Nakamura, K. Effects of glycosylation on the conformation and antigenicity of influenza C viral glycoproteins, 223
Hosaka, Y., Sasao, F. and Ohara, R. Cell-mediated lysis of heat-inactivated influenza virus-coated murine target, 245
Hudecz, F., Gonczol, E. and Plotkin, S.A. Preparation of highly purified human cytomegalovirus envelope antigen, 300
Iida, J. *see* Ishihara, C., 370
Irons, L.I. *see* Robinson, A., 11
Ishihara, C., Hamada, N., Yamamoto, K. Iida, J., Azuma, I. and Yamamura, Y. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice, 370
Jabbar, M.A. *see* Nayak, D.P., 165
Jackson, D.C. *see* Nestorowicz, A.N., 175
Jasman, R.L. *see* Woodard, L.F., 137
Jeggo, M.H. and Wardley, R.C. Bluetongue vaccine: cells and/or antibodies, 57
Jiménez-Paredes, J. *see* García-Sáinz, J.A., 23
Johannsen, R., Moser, H., Hinz, J., Friesen, H.-J. and Gruschkau, H. Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion, 235
Johnson, P.R. *see* Wright, P.F., 305
Joo, I. *see* Stanislavsky, E.S., 128
Kendal, A.P., Patriarca, P.A. and Arden, N.H. Policies and outcomes for control of influenza among the elderly in the USA, 274
Kark, J.D., Aynor, Y. and Peters, C.J. A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal *versus* subcutaneous injection, 117
Karzon, D.T. *see* Wright, P.F., 305
Kattamis, C. *see* Matsaniotis, N., 297
Katz, J.M., Brown, L.E., Ffrench, R.A. and White, D.O. Murine helper T lymphocyte response to influenza virus: recognition of haemagglutinin by subtype-specific and cross-reactive T cell clones, 257
Kendal, A.P. and Cox, N.J. Forecasting the epidemic potential of influenza virus variants based on their molecular properties, 263
Kida, H. *see* Shimizu, K., 207
Khaitov, R.M. *see* Petrov, R.V., 392
Kharitonenkov, I.G. *see* Petrov, R.V., 392
Kida, H., Yoden, S. Kuwabara, M. and Yanagawa, R. Interference with a conformational change in the haemagglutinin molecule of influenza virus by antibodies as a possible neutralization mechanism, 219

Kitame, F., Nakamura, K., Saito, A., Sinohara, H. and Homma, M. Isolation and characterization of influenza C virus inhibitors in rat serum, 211
Klenk, H.-D. *see* Garten, W., 227
Klenk, H.-D. *see* Herrler, G., 205
Kolker, I.I. *see* Krokhina, M.A., 316
Kolker, I.I. *see* Stanislavsky, E.S., 128
Koskela, P. Humoral immunity induced by a live *Francisella tularensis* vaccine. Complement fixing antibodies determined by an enzyme-linked immunosorbent assay (CF-ELISA), 389
Krokhina, M.A., Grishina, I.A., Panova, Yu.M., Terekhova, R.P., Severtsova, M.K., Yedvabnaya, L.S., Vaide, M., Varro, R., Rusanov, V.M., Kolker, I.I. and Stanislavsky, E.S. Vaccines against *Pseudomonas aeruginosa* infection: 2. Clinico-immunological investigations, 316
Krugman, S. *see* Papaevangelou, G., 31
Kuroda, K. *see* Garten, W., 227
Kuwabara, M. *see* Kida, H., 219
Lafaix, Ch. *see* Cadoz, M., 340
Langley, D. *see* McCullough, K.C., 59
Laskari, S. *see* Matsaniotis, N., 297
Lee, J.M. and Stephenson, J.R. Antigenic relationships between an isolate of the Western Subtype of tick-borne encephalitis virus and an inactivated vaccine derived from it, 292
Lehner, T. Immunization against dental caries, 65
Leib, L.E. *see* Strassburg, M.A., 109
Liew, F.Y. *see* Brand, C.M., 252
Lionelli, G. *see* Nayak, D.P., 165
Lynn, M. *see* Cabrera-Contreras, R., 103
Maasab, H.F. and DeBorde, D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines, 355
Mashilova, G.M. *see* Stanislavsky, E.S., 128
Matsaniotis, N., Kattamis, C., Dionyssopoulou, E. and Laskari, S. Immunogenicity of low doses of hepatitis B vaccine in normal children, 297
Matsunaga, M. *see* Suzuki, Y., 201
Matsumoto, M. *see* Suzuki, Y., 201
McCullough, K.C. and Langley, D. Anti-idotope vaccines: can they exist?, 59
McDonel, J.L. *see* Dorner, F., 94
McQueen, N.L. *see* Nayak, D.P., 165
McMillan, B. *see* Shuaib, M.A., 385
Mehta, S., Patel, K., Oxford, J.S. and Pasternak, C.A. Interaction of influenza virus haemagglutinin with cell membranes, 199
Melling, J. *see* Buchan, A., 49
Meunier, D.-M.-Y. *see* Georges, A.-J., 313
Morein, B. and Simons, K. Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes, 83
Moser, H. *see* Johannsen, R., 235
Mukaigawa, J. *see* Shimizu, K., 207
Muskett, J.C., Reed, N.E. and Thornton, D.H. Increased virulence of an infectious bursal disease live virus vaccine after passage in chicks, 309
Nagao, Y. *see* Suzuki, Y., 201
Nakajima, K. *see* Nobusawa, E., 172
Nakajima, K. *see* Shimizu, K., 207
Nakajima, S. *see* Nobusawa, E., 172
Nakamura, K. *see* Hongo, S., 223
Nakamura, K. *see* Kitame, F., 211
Naruse, H. *see* Garten, W., 227
Nayak, D.P., Davis, A.R., McQueen, N.L., Bos, T.J., Jabbar, M.A., Sivasubramanian, N. and Lionelli, G. Biological and immunological properties of haemagglutinin and neuraminidase expressed from cloned CDNAs in prokaryotic and eukaryotic cells, 165
Nekrasov, A.V. *see* Petrov, R.V., 392
Nerome, K., Yoshioka, Y., Sakamoto, S. Yasuhara, H. and Oya, A. Characteristics of a swine recombinant virus isolated in 1980: recombination between swine and the earliest Hong Kong (H3N2) viruses, 267
Nestorowicz, A.N., White, D.O. and Jackson, D.C. Conformational changes in influenza virus haemagglutinin and its monomer detected by monoclonal antibodies, 175
Niklasson, B., Peters, C.J., Bengtsson, E. and Norrby, E. Rift Valley fever virus vaccines trial: study of neutralizing antibody response in humans, 123
Nishi, N. *see* Nishimura, K., 379
Nishimura, K., Nishimura, S.-I., Nishi, N., Numata, F., Tone, Y., Tokura, S. and Azuma, I. Adjuvant activity of chitin derivatives in mice and guinea-pigs, 379
Nishimura, S.-I. *see* Nishimura, K., 379
Nobusawa, E., Nakajima, K. and Nakajima, S. Expression of haemagglutinin gene, 172
Norimov, A.S. *see* Petrov, R.V., 392
Norrby, E. *see* Niklasson, B., 123
Numata, F. *see* Nishimura, K., 379
Oguro, M. *see* Shimizu, K., 207
Ohara, R. *see* Hosaka, Y., 245
Ohnishi, S.I. Interaction of haemagglutinin with target membranes, 204
Ono, Y. *see* Shimizu, K., 207
Oxford, J.S. *see* Mehta, S., 199
Oya, A. *see* Nerome, Y., 267
Panova, Yu.M. *see* Krokhina, M.A., 316
Papaevangelou, G., Roumeliotou-Karayannis, A., Tassopoulous, N., Richardson, S.C. and Krugman, S. Post-exposure active immunoprophylaxis of spouses of acute viral hepatitis B patients, 31
Pasternak, C.A. *see* Mehta, S., 199
Patel, K. *see* Mehta, S., 199
Patriarca, P.A. *see* Kendal, A.P., 274
Paul, J.A. *see* Tannock, G.A., 277
Paul, J.A. *see* Tannock, G.A., 333
Perrillo, R.P. *see* Regenstein, F.G., 27
Perrin, P., Thibodeau, L. and Sureau, P. Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies, 325
Peters, C.J. *see* Kark, J.D., 117
Peters, C.J. *see* Niklasson, B., 123
Petrov, R.V., Khaitov, R.M., Zhdanov, V.M., Sinyakov, M.S., Norimov, A.S., Nekrasov, A.V., Podchernyaeva, R.Y., Kharitonenkov, I.G. and Shchipanova, M.V. Influenza virus antigens conjugated with a synthetic polyeletrolyte – a novel model of vaccines, 392
Pfeifer, J.B. and Compans, R.W. Structure and variation of the influenza C glycoprotein, 189
Plescia, O. *see* Cabrera-Contreras, O., 103
Plotkin, S.A. *see* Hudecz, F., 300
Podchernyaeva, R.Y. *see* Petrov, R.V., 392
Reed, N.E. *see* Muskett, J.C., 309
Regenstein, F.G., Perrillo, R.P., Bodicky, C., Stern, K. and Zelman, S. Clinical and immunologic features of chronic dialysis patients who fail to respond to hepatitis B vaccine, 27
Richardson, S.C. *see* Papaevangelou, G., 31
Robinson, A., Irons, L.I. and Ashworth, L.A.E. Pertussis vaccine: present status and future prospects, 11
Roumeliotou-Karayannis, A. *see* Papaevangelou, G., 31
Rowlands, D. J. Novel approaches to foot and mouth disease vaccination, 37
Ruiz-Puente, J. *see* García-Sáinz, J.A., 23
Rusanov, V.M. *see* Krokhina, M.A., 316
Saito, A. *see* Kitame, F., 211
Sakamoto, S. *see* Nerome, K., 267
Sasao, F. *see* Hosaka, Y., 245
Scalzo, A.A. *see* Anders, E.M., 241
Schuy, W. *see* Garten, W., 227
Scholtissek, C. *see* Garten, W., 227
Scholtissek, C. Stability of infectious influenza A viruses at low pH and at elevated temperature, 215
Severtsova, M.K. *see* Krokhina, M.A., 316
Severtsova, M.K. *see* Stanislavsky, E.S., 128
Shchipanova, M.V. *see* Petrov, R.V., 392
Shimizu, K., Mukaigawa, J., Oguro, M., Ono, Y., Nakajima, K. and Kida, H. Inhibition of transcriptase activity of influenza A virus *in vitro* by anti-haemagglutinin antibodies, 207
Shuaib, M.A., Spalatin, J., McMillan, B. and Hanson, R.P. Studies on the development of pelleted Newcastle disease virus (NDV) vaccines, 385
Simons, K. *see* Morein, B., 83
Sinohara, H. *see* Kitame, F., 211
Sinyakov, M.S. *see* Petrov, R.V., 392
Sissoko-Dybdahl, N.-R. *see* Georges, A.-J., 313

Sivasubramanian, N. *see* Nayak, D.P., 165
Skinner, G.R.B. *see* Buchan, A., 49
Solotorovsky, M. *see* Cabrera-Contreras, R., 103
Spalatin, J. *see* Shuaib, M.A., 385
Stanislavsky, E.S., Joo, I., Mashilova, G.M., Boolk, V.F., Boltutsy, L.G., Zakgeim, D.A., Severtsova, M.K., Yedvabnaya, L.S., Gladus, M.A., Fatkhinurova, T.I., Kolker, I.I., Grishina, I.A., Terekhova, R.P. and Zhavanetskaya, M.I. Vaccines against *Pseudomonas aeruginosa* infection: 1. Experimental studies, 128
Stanislavsky, E.S. *see* Krokhina, M.A., 316
Steenbakkers, P.G.A. *see* van Meel, F.C.M., 375
Stephenson, J.R. *see* Lee, J.M., 292
Stephenson, J.R. Rational design of vaccines against enveloped RNA viruses, 69
Stephenson, T.G. *see* Strassburg, M.A., 109
Stern, K. *see* Regenstein, F.G., 27
Stewart-Tull, D.E.S. Immunopotentiating conjugates, 40
Stirm, S. *see* Herrler, G., 205
Strassburg, M.A., Greenland, S., Stephenson, T.G., Weiss, B.P., Auerbach, D., Habel, L.A. and Lieb, L.E. Clinical effectiveness of rubella vaccine on a college population, 109
Stocker, D. *see* Buchan, A., 49
Sugawara, K. *see* Hongo, S., 223
Sureau, P. *see* Perrin, P., 325
Suzuki, Y., Matsunaga, M., Nagao, Y., Taki, T., Hirabayashi, Y. and Matsumoto, M. Ganglioside GM1b as an influenza virus receptor, 201
Taki, T. *see* Suzuki, Y., 201
Tannock, G.A., Bryce, D.A. and Paul, J.A. Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-*ca*, 333
Tannock, G.A., Paul, J.A. and Barry, R.D. Immunization against influenza by the ocular route, 277
Taranger,, J. *see* Böttiger, M., 113
Tassopoulos, N. *see* Papevangelou, G., 31
Terekhova, R.P. *see* Krokhina, M.A., 316
Terekhova, R.P. *see* Stanislavsky, E.S., 128
Thibodeau, L. *see* Boudreault, A., 231
Thibodeau, L. *see* Perrin, P., 325
Thompson, J. *see* Wright, P.F., 305
Thornton, D.H. *see* Muskett, J.C., 309
Tible, F. *see* Georges, A.-J., 313
Tokura, S. *see* Nishimura, K., 379
Tone, Y. *see* Nishimura, K., 379
Tramont, E.C. and Boslego, J.W. Pilus vaccines, 3
Vaide, M. *see* Krokhina, M.A., 316
van Meel, F.C.M., Steenbakkers, P.G.A. and Bos, E. Quantitative assay for the transforming DNA activity in cell culture products for human use, 375
Varro, R. *see* Krokhina, M.A., 316
Villava-Posanda, H. *see* García-Sáinz, J.A., 23
Wardley, R.C. *see* Jeggo, M.H., 57
Wardley, R.C. and Wilkinson, P.J. An immunological approach to vaccines against African swine fever virus, 54
Webster, R.G. *see* Yamada, A., 195
Weiss, B.P. *see* Strassburg, M.A., 109
White, D.O. *see* Anders, E.M., 241
White, D.O. *see* Katz, J.M., 257
White, D.O. *see* Nestorowicz, A.N., 175
Wiblin, C. *see* Buchan, A., 49
Wilkinson, P.J. *see* Wardley, R.C., 54
Wild, T.F. Measles vaccination — is a new strategy needed in Third World countries?, 282
Woodard, L.F. and Jasman, R.L. Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants, 137
Wright, P.F., Bhargava, M., Johnson, P.R., Thompson, J. and Karzon, D.T. Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes, 305
Yamada, A., Brown, L.E. and Webster, R.G. Antigenic analysis of H2 influenza virus haemagglutinin with monoclonal antibodies, 195
Yamamoto, K. *see* Ishihara, C., 370
Yamamura, Y. *see* Ishihara, C., 370
Yanagawa, R. *see* Kida, H., 219
Yasuhara, H. *see* Nerome, K., 267
Yedvabnaya, L.S. *see* Krokhina, M.A., 316
Yedvabnaya, L.S. *see* Stanislavsky, E.S., 128
Yoden, S. *see* Kida, H., 219
Yoshioka, Y. *see* Nerome, K., 267
Yunaji, G. *see* Elliott, R.M., 182
Zahradnik, J.M., Heiberg, D. and Hollinger, F.B. Hepatitis B vaccine: immune responses in children from families with an HBsAg carrier, 407
Zakgeim, D.A. *see* Stanislavsky, E.S., 128
Zhdanov, V.M. *see* Petrov, R.V., 392
Zhvanetskaya, M.I. *see* Stanislavsky, E.S., 128
Zelman, S. *see* Regenstein, F.G., 27

Subject Index

Acellular preparations: Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation, 23
Adjuvants: Adjuvant activity of chitin derivatives in mice and guinea-pigs, 379
Adjuvants: Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice, 370
Adjuvants: Enhance of immunogenic activity of ribosomal preparations from *Haemophilus influenzae* by various ——, 103
Adjuvants: Immunopotentiating conjugates, 40
Adjuvants: Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic ——, 137
African swine fever: An immunological approach to vaccines against —— virus, 54
Antibody formation: Adjuvant activity of chitin derivatives in mice and guinea-pigs, 379
Antibody response: Rift Valley fever virus vaccine trial: study of neutralizing —— in humans, 123
Antibody: Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants, 137
Antigenic site: Novel approaches to foot and mouth disease vaccination, 37
Assay: Quantitative —— for the transforming DNA activity in cell culture products for human use, 375
Attenuated virus: Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-*ca*, 333
Bacteria: Bacterial toxin vaccines, 94
Bacteria: Pilus vaccines, 3
Bacteria: Vaccines against *Pseudomonas aeruginosa* infection: 1. Experimental studies, 128
Biological activity: Comparative —— of whole cell pertussis vaccine and a new cellular preparation, 23
Bluetongue virus: —— vaccine: cells and/or antibodies, 57
Bluetongue virus: Immunogencity of —— inactivated by gamma-irradiation, 401
Bordetella pertussis: Pertussis vaccine: present status and future prospects, 11
Bursal disease: Increased virulence of an infectious —— live virus vaccine after passage in chicks, 309
Cattle: Vaccination against enteric rota and coronaviruses in —— and pigs: enhancement of lactogenic immunity, 384
Cell culture: Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attentuated influenza virus master

strain A/Ann/Arbor/6/60-*ca*, 333
Cell culture: Quantitative assay for the transforming DNA activity in —— products for human use, 375
Cell-mediated lysis: —— of heat-inactivated influenza virus-coated murine targets, 245
Cell membranes: Interaction of influenza virus haemagglutinin with ——, 199
Cellular receptor: Ganglioside GM1b as an influenza virus receptor, 201
Cellular receptor: Inhibition with rat α_1-macroglobulin of haemagglutinin by influenza C virus, 205
Chickens: Studies on the development of pelleted Newcastle disease virus (NDV) vaccines, 385
Chicks: Increase virulence of an infectious bursal disease live virus vaccine after passage in ——, 309
Children: Hepatitis B vaccine: Immune responses in —— from families with an HBsAg carrier, 407
Children: Immunogenicity of low doses of hepatitis B vaccine in normal ——, 297
Children: Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of ——, 113
Children: Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes, 305
Children: Tetravalent (A,C,Y,W 135) meningococcal vaccine in ——: immunogenicity and safety, 340
Children: Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine, 313
Chitin: Adjuvant activity of —— derivatives in mice and guinea-pigs, 379
Clinical effectiveness: —— of rubella vaccine in a college population, 109
Clinical trial: Vaccines against *Pseudomonas aeruginosa* infection: 2. Clinico-immunological investigations, 316
Cold-adapted: Development and characterization of —— viruses for use as live virus vaccines, 355
Complement fixation: Humoral immunity induced by a live *Francisella tularensis* vaccine. Complement fixing antibodies determined by a enzyme-linked immunosorbent assay (CF-ELISA), 389
Conference reports: 77, 149, 347
Conformation: Interference with a conformational change in the haemagglutinin molecule on influenza virus by antibodies as a possible neutralization mechanism, 219
Conjugates: Immunopotentiating ——, 40
Controlled release: Prospects for improved foot and mouth disease vaccines, 35
Coronavirus: Vaccination against enteric rota and coronaviruses in cattle and pigs: enhancement of lactogenic immunity, 284
Cytomegalovirus: Preparation of highly purified human —— envelope antigen, 300
Deacylated chitin: Adjuvant activity of chitin derivatives in mice and guinea-pigs, 379
Delayed-type hypersensitivity: Adjuvant activity of chitin derivatives in mice and guinea-pigs, 379
Dental caries: Immunization against ——, 65
Dialysis: Clinical and immunologic features of chronic —— patients who fail to respond to hepititis B vaccine, 27
DNA: Quantitative assay for the transforming —— activity in cell culture products for human use, 375
Editorials: 82, 354
Elderly: Policies and outcomes for control of influenza among the —— in the USA, 274
Emulsions: Stable oil-in-water: preparation and use as vaccine vehicles for lipophilic adjuvants, 137
Encephalitis: Antigenic relationships between an isolate of the Western Subtype of tick-borne —— virus and an inactivated vaccine derived from it, 292
Enveloped RNA viruses: Rational design of vaccines against ——, 69
Enveloped viruses: Subunit vaccines against —— virosomes. micelles and other protein complexes, 83
Enzyme-linked immunosorbent assay: Humoral immunity induced by a live *Francisella tularensis* vaccine. Complement fixing antibodies determined by an —— (CF-ELISA), 389
Epidemic: Forecasting the —— potential of influenza virus variants based on their molecular properties, 263
Field trial: Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine, 313
Fimbriae: Pilus vaccines, 3
Flavirus: Antigenic relationships between an isolate of the Western Subtype of tick-borne encephalitis virus and an inactivated vaccine derived from it, 292
Foot and mouth disease: Novel approaches to —— vaccination, 37
Foot and mouth disease vaccine: Prospects for improved —— vaccines, 35
Francisella tularensis: Humoral immunity induced by a live —— vaccine. Complement fixing antibodies determined by an enzyme-linked immunosorbent assay (CF-ELISA), 389
Gamma-irradiation: Immunogenicity of bluetongue virus inactivated by ——, 401
Glycoproteins: Effects of glycosylation on the conformation and antigenicity of influenza C viral ——, 223
Glycoprotein: Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies, 325
Glycoprotein: Structure and variation of the influenza C ——, 189
Haemagglutinin: Antigenic analysis of H2 influenza virus —— with monoclonal antibodies, 195
Haemagglutinin: Biological and immunological properties of —— and neuraminidase expressed from cloned cDNAs in prokaryotic and eukaryotic cells, 165
Haemagglutinin: Conformational changes in influenza virus —— and its monomer detected by monoclonal antibodies, 175
Haemagglutinin: Ganglioside GM1b as an influenza virus receptor, 201
Haemagglutinin gene: Expression of ——, 172
Haemagglutinin: —— transport mutants, 227
Haemagglutinin: Host antigens associated with ——, 252
Haemagglutinin: Inhibition of transcriptase activity of influenza A virus *in vitro* by anti —— antibodies, 207
Haemagglutinin: Inhibition with rat α_1-macroglobulin of —— by influenza C virus, 205
Haemagglutinin: Interaction of —— with target membranes, 204
Haemagglutinin: Interaction of influenza virus —— with cell membranes, 199
Haemagglutinin: Interference with a conformational change in the —— molecule on influenza virus by antibodies as a possible neutralization mechanism, 219
Haemagglutinin: Mitogenic activity of influenza virus and ——, 241
Haemagglutinin: Murine helper T lymphocyte response to influenza virus: recognition of —— by subtype-specific and cross-reactive T cell clones, 257
Haemagglutinin: Quantification of —— of influenza Tween-ether split vaccines by immunodiffusion, 235
Haemophilus influenzae: Enhancement of immunogenic activity of ribosomal preparations from —— by various adjuvants, 103
Hepatitis B vaccine: Clinical and immunologic features of chronic dialysis patients who fail to repond to ——, 27
Hepatitis B vaccine: —— immune responses in children from families with a HBsAg carrier, 407
Hepatitis B vaccine: Post exposure active immuno-prophylaxis of spouses of acute viral hepatitis B patients, 31
Hepatitis: Immunogenicity of low doses of —— B vaccine in normal children, 297

Herpes simplex: Control of —— virus infections of the genital tract by vaccination, 49
Human: Preparation of highly purified —— cytomegalovirus envelope antigen, 300
Idiotopes: Anti-idiotope vaccine: can they exist?, 59
Immune response: Anti-idiotope vaccines: can they exist?, 59
Immunogenes: Viral and bacterial vectors of ——, 45
Immunogenicity: Enhancement of immunogenic activity of ribosomal preparations from *Haemophilus influenzae* by various adjuvants, 103
Immunopotentiating conjugates, 40
Immunosomes: Mouse response to influenza, 231
Immunosomes: Rabies —— (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies, 325
Infectious bursal disease: Increased virulence of an —— live virus vaccine after passage in chicks, 309
Influenza A: Stability of infectious —— viruses at low pH and at elevated temperature, 215
Influenza: Antigenic analysis of H2 —— virus haemagglutinin with monoclonal antibodies, 195
Influenza: Biological and immunological properties of haemagglutinin and neuraminidase expressed from cloned cDNAs in prokaryotic and eukaryotic cells, 165
Influenza C: Conformational changes in influenza virus haemagglutinin and its monomer detected by monoclonal antibodies, 175
Influenza C: Effects of glycosylation on the conformation and antigencity of —— viral glycoproteins, 223
Influenza C: Ganglioside GM1b as an influenza virus receptor, 201
Influenza C: Inhibition with rat α_1-macroglobulin of haemagglutinin by —— virus, 205
Influenza C: Isolation and characterization of —— virus inhibitors in rat serum, 211
Influenza C: Protein and nucleic acid analyses of —— viruses isolated from pigs and man, 182
Influenza C: Structure and variation of the —— glycoprotein, 189
Influenza: Cell-mediated lysis of heat-inactivated influenza virus-coated murine targets, 245
Influenza: Characteristics of a swine recombinant —— virus isolated in 1980: recombination between swine and the earliest Hong Kong (H3N2) viruses, 267
Influenza: Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated —— virus master strain A/Ann/Arbor/6/60-*ca*, 333
Influenza: Expression of haemagglutinin gene, 172
Influenza: Forecasting the epidemic potential of influenza virus variants based on their molecular properties, 263
Influenza: Haemagglutinin transport mutants, 227
Influenza: Host antigens associated with haemaggiutinin, 252
Influenza: Immunization against —— by the ocular route, 277
Influenza: Inhibition of transcriptase activity of —— A virus *in vitro* by anti-haemagglutinin antibodies, 207
Influenza: Interaction of haemagglutinin with target membranes, 204
Influenza: Interaction of —— virus haemagglutinin with cell membranes, 199
Influenza: Interference with a conformational change in the haemagglutinin molecule on —— virus by antibodies as a possible neutralization mechanism, 219
Influenza: Mitogenic activity of —— virus and haemagglutinin, 241
Influenza: Mouse reponse to —— immunosomes, 231
Influenza: Murine helper T lymphocyte response to —— virus: recognition of haemagglutinin by subtype-specific and cross-reactive T cell clones, 257
Influenza: Policies and outcomes for control of —— among the elderly in the USA, 274
Influenza: Simultaneous administration of live, attenuated —— A vaccines representing different serotypes, 305
Influenza: Quantification of haemagglutinin of —— Tween-ether split vaccines by immunodiffusion, 235
Influenza virus: —— antigens conjugated with a synthetic polyelectrolyte – a novel model of vaccines, 392
Live attenuated vaccine: Simultaneous administration of ——, influenza A vaccines representing different serotypes, 305
Live virus vaccines: Development and characterization of cold-adapted viruses for use as ——, 355
Measles: Mass vaccination programme aimed at eradicating ——, mumps and rubella in Sweden: vaccination of school children, 113
Measles: —— vaccination – is a new strategy needed in the Third World countries?, 282
Meningococci: Tetravalent (A,C,Y,W 135) —— vaccine in children: immunogenicity and safety, 340
Micelles: Subunit vaccines against enveloped viruses: virosomes, —— and other protein complexes, 83
Mitogenic activity: —— of influenza virus and haemagglutinin, 241
Monoclonal antibodies: Antigenic analysis of H2 influenza virus haemagglutinin with ——, 195
Monoclonal antibodies: Antigenic relationships between an isolate of the Western Subtype of tick-borne encephalitis virus and an inactivated vaccine derived from it, 292
Monoclonal antibodies: Conformational changes in influenza virus haemagglutinin and its monomer detected by ——, 175
Mumps: Mass vaccination programme aimed at eradicating measles, —— and rubella in Sweden: vaccination of school children, 113
Muramyl dipeptide: Effect of —— and its stearoyl derivatives on resistance to Sendai virus infection in mice, 370
Neuraminidase: Biological and immunological properties of haemagglutinin and —— expressed from cloned cDNAs in prokaryotic and eukaryotic cells, 165
Newcastle disease vaccine: Studies on the development of pelleted —— virus (NDV) vaccines, 385
Obituary: 2
Ocular route: Immunization against influenza by the ——, 277
Oligonucleotide mapping: Protein and nucleic acid analyses of influenza C viruses isolated from pigs and man, 182
Oncogene: Quantitative assay for the transforming DNA activity in cell culture products for human use, 375
Patent reports: 73, 145, 343, 414
Pelleted vaccine: Studies on the development of pelleted Newcastle disease virus (NDV) vaccines, 385
Peptidoglycans: Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice, 370
Pertussis vaccine: Comparative biological activities of whole cell —— and a new acellular preparation, 23
Pertussis vaccine: present status and future prospects, 11
Pigs: Vaccination against enteric rota and coronaviruses in cattle and ——: enhancement of lactogenic immunity, 284
Pili: Pilus vaccines, 3
Policy: Policies and outcomes for control of influenza among the elderly in the USA, 274
Polyelectrolyte: Influenza virus antigens conjugated with a synthetic —— a novel model of vaccines, 392
Pseudomonas aeruginosa: Vaccines against —— infection: 1. Experimental studies, 128
Pseudomonas aeruginosa: Vaccines against —— infection: 2. Clinico-immunological investigations, 316
Public health: Clinical effectiveness of rubella vaccine in a college population, 109
Pyoimmunogen: Vaccines against *Pseudomonas aeruginosa* infection: 2. Clinico-immunological investigations, 316
Rabies: Post-exposure —— prophylaxis: establishing effectiveness of abbreviated treatments, 283

Rabies: —— immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies, 325
Recombinant DNA: Rational design of vaccines against enveloped RNA viruses, 69
Recombinant virus: Characteristics of a swine recombinant influenza virus isolated in 1980: recombination between swine and the earliest Hong Kong (H3N2) viruses, 267
Ribosomes: Enhancement of immunogenic activity of ribosomal preparations from *Haemophilus influenzae* by various adjuvants, 103
Rift Valley fever: A vaccine trial: 2. Serological response to booster doses with a comparison of intradermal *versus* subcutaneous injection, 117
Rift Valley fever —— virus vaccine trial: study of neutralizing antibody response in humans, 123
RNA virus: Bluetongue vaccine: cells and/or antibodies, 57
RNA viruses: Rational design of vaccines against enveloped ——, 69
Rotavirus: Vaccination against enteric rota and coronaviruses in cattle and pigs: enhancement of lactogenic immunity, 284
Route: A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal *versus* subcutaneous injection, 117
Rubella: Mass vaccination programme aimed at eradicating measles, mumps and —— in Sweden: vaccination of school children, 113
Rubella vaccine: Clinical effectiveness of —— in a college population, 109
Safety: Pertussis vaccine: present status and future prospects, 11
Seroconversion: Hepatitis B vaccine: immune responses in children from families with HBsAg carrier, 407
Serological response: A Rift Valley fever vaccine trial: 2. —— to booster doses with a comparison of intradermal *versus* subcutaneous injection, 117
Serum: Isolation and characterization of influenza C virus inhibitors in rat ——, 211
Stability: —— of infectious influenza A viruses at low pH and at elevated temperature, 215
Stability: Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine, 313
Streptococcus mutans: Immunization against dental caries, 65
Subunit vaccines: —— against enveloped viruses: virosomes, micelles and other protein complexes, 83
Surrogate antigen: Anti-idiotope vaccines: can they exist?, 59
Synthetic peptides: Novel approaches to foot and mouth disease vaccination, 37
Target membranes: Interaction of haemagglutinin with ——, 204
Teeth: Immunization against dental caries, 65
Tick-borne: Antigenic relationships between an isolate Western Subtype of —— encephalitis virus and an inactivated vaccine derived from it, 292
T-lymphocytes: Murine helper T lymphocyte response to influenza virus: recognition of haemagglutinin by subtype-specific and cross-reactive T cell clones, 257
Togavirus: Antigenic relationships between an isolate of the Western Subtype of tick-borne encephalitis virus and an inactivated vaccine derived from it, 292
Trial: Immunogencity of low doses of hepatitis B vaccine in normal children, 297
Trial: Post-exposure active immunoprophylaxis of spouses of acute viral hepatitis B patients, 31
Trial: A Rift Valley fever vaccine ——: 2. Serological response to booster doses with a comparison of intradermal *versus* subcutaneous injection, 119
Trial: Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans, 123
Transcriptase: Inhibition of —— activity of influenza A virus *in vitro* by anti-haemagglutinin antibodies, 207
Toxins: Bacterial toxin vaccines, 94
Vaccination programme: Mass —— aimed at eradicating measles, mumps and rubella in Sweden: vaccination of school children, 113
Vaccine development: Bacterial toxin vaccines, 94
Vaccine preparation: Vaccines against *Pseudomonas aeruginosa* infection: 1. Experimental studies, 128
Vaccinia virus: Viral and bacterial vectors of immunogenes, 45
Vectors: Viral and bacterial —— of immunogenes, 45
Viral infections: Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice, 370
Virogates: Influenza virus antigens conjugated with a synthetic polyelectrolyte - a novel model of vaccines, 392
Virosomes: Subunit vaccines against enveloped viruses: ——, micelles and other protein complexes, 83
Virus: Development and characterization of cold-adapted viruses for use as live —— vaccines, 355
Viruses: Subunit vaccines against enveloped ——: virosomes, micelles and other protein complexes, 83
Virus inhibitors: Isolation and characterization of influenza C —— in rat serum, 211
Whooping cough: Pertussis vaccine: present status and future prospects, 11
Yellow fever: Thermostability and efficacy in the field of a new, stabilized —— virus vaccine, 313